BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in several
- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients - - On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 - - Planned 4STEPS
BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual
- Repayment of Existing Loan Facility Completed -- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the
- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026
